Covid-19 Banner

NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx® Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

New solicitations: read the media advisory about two new RADx Tech funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 tests with a major focus on accessibility and improved test performance.  

Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs

The RADx® Tech program is part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. 

Summary data on proposals submitted to the RADx® Tech and ATP Programs.

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

Listing of COVID-19 related grants funded by NIBIB.

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.


View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADx® Tech/ATP programmatic or technical inquiries:

All other RADx® Tech/ATP Applicants:

SBIR/STTR Applicants:

All others:

Related News

November 22, 2022
Light blue map of the United States overlayed with Make My Test
Reporting a positive or negative test result just became easier through a new website from the National Institutes of Health., developed through NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program, allows users to anonymously report the results of any brand of at-home COVID-19 test.
October 28, 2022
NIBIB Director Bruce Tromberg talked about his love of lasers, the light-speed advances in optics and photonics he’s witnessed and contributed to throughout his career, and the unique role that NIBIB has played in NIH’s COVID-19 response in this interview with NIH MedlinePlus magazine. Source: MedlinePlus Magazine
October 17, 2022
stylized snake design
NIBIB Director Bruce J. Tromberg, Ph.D., has been elected to membership in the National Academy of Medicine.
September 15, 2022
Illustration of SARS-CoV-2 viral particles in different colors on a blue background
A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.
September 9, 2022
NIH announced it will provide funding to diagnostic test manufacturers for the development of the next generation of COVID-19 tests, with a focus on improved accessibility. Source: LabPulse